yes
true
Permitted Uses and Disclosures. A covered entity is permitted, but not required, to use and disclose protected health information, without an individual's authorization, for the following purposes or situations: (1) To the Individual (unless required for access or accounting of disclosures); (2) Treatment, Payment, and Health Care Operations; (3) Opportunity to Agree or Object; (4) Incident to an otherwise permitted use and disclosure; (5) Public Interest and Benefit Activities; and (6) Limited Data Set for the purposes of research, public health or health care operations. Covered entities may rely on professional ethics and best judgments in deciding which of these permissive uses and disclosures to make.
Source: Summary of the HIPPA Privacy rule posted on the HHS web site.
no
yes
In regards to HIPAA recert… answer is TRUE
You can request a history of disclosures for six years prior to the request, except for disclosures made for treatment, payment, healthcare operations or with prior authorization
Yes
A: notice of use and disclosure, which is required for every patient that a health provider treats is part of the standard procedures for new patients. Pg 3
patients who have never before received the treatment in question
Chemonucleolysis should not be performed on patients allergic to chymopapain or papaya. It also should not be done: when the patient is pregnant, if the disk is sequestered, if the patient has had several failed back operations.
A new treatment option for patients with lymphoma is known as "peripheral stem cell transplantation."
submit a request to an institutional review board if he does not get authorization from all patients.
Bariatric operations alter the digestive tract of patients in order to achieve weight loss in individuals who are obese. Surgery candidates generally have a BMI over 40 or have an obesity-related disease.
Most patients with Campylobacter infection rapidly recover without treatment. For certain groups of patients, infection becomes chronic and requires repeated courses of antibiotics.
Patients with metastatic melanoma who do not respond well to other therapies may be candidates for treatment with aldesleukin.
no no
triage